DDInter1943 DDInter1840
In 1922, vitamin E was demonstrated to be an essential nutrient. Vitamin E is a term used to describe 8 different fat soluble tocopherols and tocotrienols, alpha-tocopherol being the most biologically active. Vitamin E acts as an antioxidant, protecting cell membranes from oxidative damage. The antioxidant effects are currently being researched for use in the treatment of diseases causing bone loss, cardiovascular diseases, diabetes mellitus and associated comorbidities, eye diseases, inflammatory diseases (including skin conditions), lipid disorders, neurological diseases, and radiation damage. Though this research is so far inconclusive, vitamin E remains a popular supplement and is generally considered safe by the FDA[FDA Label].
Trabectedin, also referred as ET-743 during its development, is a marine-derived antitumor agent discovered in the Carribean tunicate _Ecteinascidia turbinata_ and now produced synthetically. Trabectedin has a unique mechanism of action. It binds to the minor groove of DNA interfering with cell division and genetic transcription processes and DNA repair machinery. It is approved for use in Europe, Russia and South Korea for the treatment of advanced soft tissue sarcoma. It is currently under evaluation for the treatment of breast cancer, prostate cancer, in addition to pediatric sarcomas. Both the European Commission and the U.S. Food and Drug Administration (FDA) have approved trabectedin as an orphan drug in soft tissue sarcomas and ovarian cancer. On October 23, 2015, the FDA approved trabectedin, (as Yondelis), for the treatment of specific soft tissue sarcomas.
Vitamin E {u} (Compound) binds {v} (Gene) DGKA
DGKA {u} (Gene) interacts with {v} (Gene) SRC
SRC {u} (Gene) is bound by {v} (Compound) Trabectedin
Vitamin E {u} (Compound) binds {v} (Gene) NR1I2
NR1I2 {u} (Gene) interacts with {v} (Gene) SRC
SRC {u} (Gene) is bound by {v} (Compound) Trabectedin
Vitamin E {u} (Compound) binds {v} (Gene) HMOX1
HMOX1 {u} (Gene) is regulated by {v} (Gene) SRC
SRC {u} (Gene) is bound by {v} (Compound) Trabectedin
Vitamin E {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Bortezomib
Bortezomib {u} (Compound) binds {v} (Gene) PTGS1
PTGS1 {u} (Gene) is bound by {v} (Compound) Trabectedin
Vitamin E {u} may cause a minor interaction that can limit clinical effects when taken with {v} Dexamethasone
Dexamethasone {u} (Compound) binds {v} (Gene) CYP2C19
CYP2C19 {u} (Gene) is bound by {v} (Compound) Trabectedin
Vitamin E {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Etoposide
Etoposide {u} (Compound) causes {v} (Side Effect) Alanine aminotransferase increased
Alanine aminotransferase increased {u} (Side Effect) is caused by {v} (Compound) Trabectedin
Vitamin E {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ifosfamide
Ifosfamide {u} (Compound) is included by {v} (Pharmacologic Class) Alkylating Activity
Alkylating Activity {u} (Pharmacologic Class) includes {v} (Compound) Trabectedin
Vitamin E {u} may cause a minor interaction that can limit clinical effects when taken with {v} Dexamethasone
Dexamethasone {u} (Compound) causes {v} (Side Effect) Weight decreased
Weight decreased {u} (Side Effect) is caused by {v} (Compound) Trabectedin
Vitamin E {u} (Compound) resembles {v} (Compound) Phylloquinone
Phylloquinone {u} (Compound) causes {v} (Side Effect) Injection site reaction
Injection site reaction {u} (Side Effect) is caused by {v} (Compound) Trabectedin
Vitamin E (Compound) binds DGKA (Gene) and DGKA (Gene) interacts with SRC (Gene) and SRC (Gene) is bound by Trabectedin (Compound)
Vitamin E (Compound) binds NR1I2 (Gene) and NR1I2 (Gene) interacts with SRC (Gene) and SRC (Gene) is bound by Trabectedin (Compound)
Vitamin E (Compound) binds HMOX1 (Gene) and HMOX1 (Gene) is regulated by SRC (Gene) and SRC (Gene) is bound by Trabectedin (Compound)
Vitamin E may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezomib (Compound) binds PTGS1 (Gene) and PTGS1 (Gene) is bound by Trabectedin (Compound)
Vitamin E may cause a minor interaction that can limit clinical effects when taken with Dexamethasone and Dexamethasone (Compound) binds CYP2C19 (Gene) and CYP2C19 (Gene) is bound by Trabectedin (Compound)
Vitamin E may cause a moderate interaction that could exacerbate diseases when taken with Etoposide and Etoposide (Compound) causes Alanine aminotransferase increased (Side Effect) and Alanine aminotransferase increased (Side Effect) is caused by Trabectedin (Compound)
Vitamin E may cause a moderate interaction that could exacerbate diseases when taken with Ifosfamide and Ifosfamide (Compound) is included by Alkylating Activity (Pharmacologic Class) and Alkylating Activity (Pharmacologic Class) includes Trabectedin (Compound)
Vitamin E may cause a minor interaction that can limit clinical effects when taken with Dexamethasone and Dexamethasone (Compound) causes Weight decreased (Side Effect) and Weight decreased (Side Effect) is caused by Trabectedin (Compound)
Vitamin E (Compound) resembles Phylloquinone (Compound) and Phylloquinone (Compound) causes Injection site reaction (Side Effect) and Injection site reaction (Side Effect) is caused by Trabectedin (Compound)